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Background
There are over 15 million people with food allergies,
38% of which suffer from more than 1 food allergy.
With increasing interest in oral immunotherapy (OIT)
as a potential treatment, the safety of ingesting known
allergens is a major concern. Little to no data are avail-
able for OIT with multiple simultaneous allergens. Also,
the effect of omalizumab as adjunctive therapy in rush
multi OIT had not been investigated.
Methods
After obtaining IRB approval, subjects (pediatric and
adults) were consented and enrolled in an ongoing mul-
tiple allergen OIT clinical studies: one phase 1 study
“standard multi OIT” (n=27), and a second noted as
“rush multi OIT” in which food allergen doses were
100x higher than “standard multi OIT” due to adjunct
therapy with omalizumab (n=11). Food allergens
included were milk, egg, peanut, walnut, cashew,
almond, pecan, hazelnut, wheat, soy, and/or sesame. Up
to 5 foods were allowed to be given in the OIT regimen
simultaneously depending on the subjects’ allergic reac-
tions to screening food challenges. Entry criteria for
both studies were the same; they included a positive
DBPCFC for each food allergen with positive skin prick
test and/or positive food specific IgE >7kU/L for each
food allergen. Subjects receiving omalizumab had injec-
tions between weeks 1 and 15. Subjects taking omalizu-
mab and OIT were increased on their initial dose by up
to 100 fold more than the initial dose given to subjects
taking OIT without omalizumab. Safety was the primary
outcome. The secondary goal of both studies was to
reach 4000mg of each allergen.
Results
These studies are still ongoing. At an average of 28 weeks
into studies, there have been an estimated 7471 doses in
the standard multiple OIT group, with 371 documented
clinical reactions (4.9%). There were 150 documented
clinical reactions occurring in an estimated 1076 doses
(13.9%) in the rush multiple OIT group. Reactions were
mostly mild in both groups (508 mild reactions out of
520 total reactions) and mainly consisted of abdominal
pain, pruritus, and rash. No subjects withdrew due to
adverse side effects. Six reactions (out of 8547 doses)
required epinephrine, two in the rush multi OIT study
and four in the standard multi OIT study.
Conclusion
Multiple OIT should be performed in a carefully moni-
tored hospital environment with well trained staff. More
studies are needed to obtain data on short term and long
term efficacy and safety of multi OIT to address the high
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